QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- SeaStar Medical
- Study ID
- NCT06517810
- Status
- Recruiting
Conditions
- Acute Kidney Injury
- Acute Kidney Injury Due to Sepsis
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 22 Years
- Healthy Volunteers
- Not accepted
Interventions
- QUELIMMUNE (SCD-PED) — DEVICEQUELIMMUNE device used as part of clinical practice.
Study Details
QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT. The purpose of this surveillance registry is to prospectively collect safety data among all patients treated with QUELIMMUNE under the HDE. More specifically, we intend on comparing the incidence of new (secondary) blood stream infections in the first 28 days after SCD-PED initiation to a comparator group of matched CKRT patients with sepsis who did not receive treatment with QUELIMMUNE
Key Dates
- Start date
- Jul 19, 2024
- Status verified
- May 2026
- Primary completion
- May 31, 2026
- Completion
- Aug 31, 2026
Study Design
- Enrollment
- 50 participants (estimated)
Arms
- Arm: QUELIMMUNE Surveillance Registry ParticipantsAll patients treated with the QUELIMMUNE device as a part of clinical practice under the approved HDE indication must be included in this registry.
Primary Outcome Measure
Safety [ Time Frame: 28 days or through hospital discharge, whichever is sooner ]
Central Contacts
- Mohamed Zidan, MD844-427-8100
- Kevin K Chung, MD844-427-8100
Locations (15)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's of Alabama | Birmingham | Alabama | 35233 | - |
| Lucile Packard Children's Hospital Stanford | Palo Alto | California | 94304 | - |
| UCSF Benioff Children's | San Francisco | California | 94618 | - |
| HealthONE HCA Rocky Mountain Children's Hospital | Denver | Colorado | 80205 | - |
| Children's Hospital of Atlanta - Arthur M. Blank | Atlanta | Georgia | 30329 | - |
| Children's Hospital of Atlanta - Scottish Rite | Atlanta | Georgia | 30342 | - |
| Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | - |
| CS Mott Children's Hospital | Ann Arbor | Michigan | 48109 | - |
| Cincinnati Children's Hospital | Cincinnati | Ohio | 45229 | - |
| Cleveland Clinic Children's Hospital | Cleveland | Ohio | 44106 | - |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | - |
| Monroe Carrell Jr Children's Hospital at Vanderbilt | Nashville | Tennessee | 37232 | - |
| Children's Medical Center Dallas | Dallas | Texas | 75235 | - |
| Cook Children's Hospital | Fort Worth | Texas | 76104 | - |
| Texas Children's Hospital | Houston | Texas | 77030 | - |
Find similar trials in Birmingham, AL
By research site
Children's of Alabama· Birmingham, ALLucile Packard Children's Hospital Stanford· Palo Alto, CAUCSF Benioff Children's· San Francisco, CAHealthONE HCA Rocky Mountain Children's Hospital· Denver, COChildren's Hospital of Atlanta - Arthur M. Blank· Atlanta, GAChildren's Hospital of Atlanta - Scottish Rite· Atlanta, GA
Related Studies
- Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric AKIEnrolling By Invitation · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio
- The Biosonographic IndexRecruiting · University of Alabama at Birmingham · Birmingham, Alabama
- Angiotensin 2 for AKI After OLTPHASE4 · Enrolling By Invitation · University of California, Los Angeles · Los Angeles, California
- Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn RegistryRecruiting · Potrero Medical · Los Angeles, California